Lenz & Staehelin advises Asceneuron on its agreement with Ferrer

Spanish pharmaceutical company Ferrer and Swiss clinical stage biotechnology company Asceneuron have announced the signing of a licensing agreement in which Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90 in progressive supranuclear palsy (PSP), an orphan neurological disease with a high unmet medical need.

This agreement underscores the commitments both companies have undertaken to improve the lives of patients with a rare disease, such as Progressive Supranuclear Palsy (PSP). The terms of the agreement include an upfront fee and multiple development, regulatory and commercial milestone payments. Asceneuron is also eligible to receive tiered double-digit royalties on worldwide net sales of ASN90.

Lenz & Staehelin advised Asceneuron in this transaction. The team was led by partner Sevan Antreasyan (IP, commercial and contracts, pictured) and included Anne-Laure Laplace (IP, commercial and contracts) and Federico Trabaldo Togna (corporate and m&a).